Literature DB >> 33363465

MicroRNAs Bioinformatics Analyses Identifying HDAC Pathway as a Putative Target for Existing Anti-COVID-19 Therapeutics.

Laura Teodori1, Piero Sestili2, Valeria Madiai1, Sofia Coppari2, Daniele Fraternale2, Marco Bruno Luigi Rocchi2, Seeram Ramakrishna3, Maria Cristina Albertini2.   

Abstract

Over 313,000 SARS-CoV-2 positive cases have been confirmed in Italy as of 30 September 2020, and the number of deaths exceeding thirty-five thousand makes Italy among the list of most significantly affected countries in the world. Such an enormous occurrence of infections and death raises the urgent demand for effective available treatments. Discovering the cellular/molecular mechanisms of SARS-CoV-2 pathogenicity is of paramount importance to understand how the infection becomes a disease and how to plan any therapeutic approach. In this regard, we performed an in silico analysis to predict the putative virus targets and evidence the already available therapeutics. Literature experimental results identified angiotensin-converting enzyme ACE and Spike proteins particularly involved in COVID-19. Consequently, we investigated the signalling pathways modulated by the two proteins through query miRNet, the platform linking miRNAs, targets, and functions. Our bioinformatics analysis predicted microRNAs (miRs), miR-335-5p and miR-26b-5p, as being modulated by Spike and ACE together with histone deacetylate (HDAC) pathway. Notably, our results identified ACE/ACE2-ATR1-Cholesterol-HDAC axis signals that also matched with some available clinical data. We hypothesize that the current and EMA-approved, SARS-CoV-2 off-label HDAC inhibitors (HDACis) drugs may be repurposed to limit or block host-virus interactions. Moreover, a ranked list of compounds is provided for further evaluation for safety, efficacy, and effectiveness.
Copyright © 2020 Teodori, Sestili, Madiai, Coppari, Fraternale, Rocchi, Ramakrishna and Albertini.

Entities:  

Keywords:  ACE2; COVID-19; HDAC; SARS-CoV-2; hypertension; off‐label drugs

Year:  2020        PMID: 33363465      PMCID: PMC7753186          DOI: 10.3389/fphar.2020.582003

Source DB:  PubMed          Journal:  Front Pharmacol        ISSN: 1663-9812            Impact factor:   5.810


  9 in total

1.  Demystifying the long noncoding RNA landscape of small EVs derived from human mesenchymal stromal cells.

Authors:  Chien-Wei Lee; Yi-Fan Chen; Allen Wei-Ting Hsiao; Amanda Yu-Fan Wang; Oscar Yuan-Jie Shen; Belle Yu-Hsuan Wang; Lok Wai Cola Ho; Wei-Ting Lin; Chung Hang Jonathan Choi; Oscar Kuang-Sheng Lee
Journal:  J Adv Res       Date:  2021-11-19       Impact factor: 12.822

2.  Characterizing HDAC Pathway Copy Number Variation in Pan-Cancer.

Authors:  Shuming Yang; Shengzhi Xie; Xinying Shi; Dan Su; Bo He; Yang Xu; Zhefeng Liu
Journal:  Pathol Oncol Res       Date:  2022-06-13       Impact factor: 2.874

3.  Role of miR-2392 in driving SARS-CoV-2 infection.

Authors:  J Tyson McDonald; Francisco J Enguita; Deanne Taylor; Robert J Griffin; Waldemar Priebe; Mark R Emmett; Mohammad M Sajadi; Anthony D Harris; Jean Clement; Joseph M Dybas; Nukhet Aykin-Burns; Joseph W Guarnieri; Larry N Singh; Peter Grabham; Stephen B Baylin; Aliza Yousey; Andrea N Pearson; Peter M Corry; Amanda Saravia-Butler; Thomas R Aunins; Sadhana Sharma; Prashant Nagpal; Cem Meydan; Jonathan Foox; Christopher Mozsary; Bianca Cerqueira; Viktorija Zaksas; Urminder Singh; Eve Syrkin Wurtele; Sylvain V Costes; Gustavo Gastão Davanzo; Diego Galeano; Alberto Paccanaro; Suzanne L Meinig; Robert S Hagan; Natalie M Bowman; Matthew C Wolfgang; Selin Altinok; Nicolae Sapoval; Todd J Treangen; Pedro M Moraes-Vieira; Charles Vanderburg; Douglas C Wallace; Jonathan C Schisler; Christopher E Mason; Anushree Chatterjee; Robert Meller; Afshin Beheshti
Journal:  Cell Rep       Date:  2021-09-30       Impact factor: 9.423

4.  Drug repurposing for coronavirus (SARS-CoV-2) based on gene co-expression network analysis.

Authors:  Habib MotieGhader; Esmaeil Safavi; Ali Rezapour; Fatemeh Firouzi Amoodizaj; Roya Asl Iranifam
Journal:  Sci Rep       Date:  2021-11-08       Impact factor: 4.379

Review 5.  The role of microRNAs in solving COVID-19 puzzle from infection to therapeutics: A mini-review.

Authors:  Sujay Paul; Luis Alberto Bravo Vázquez; Paula Roxana Reyes-Pérez; Carolina Estrada-Meza; Rafael Arturo Aponte Alburquerque; Surajit Pathak; Antara Banerjee; Anindya Bandyopadhyay; Samik Chakraborty; Aashish Srivastava
Journal:  Virus Res       Date:  2021-11-14       Impact factor: 3.303

6.  Bioinformatics and System Biology Approach to Identify the Influences of COVID-19 on Rheumatoid Arthritis.

Authors:  Huan Hu; Nana Tang; Facai Zhang; Li Li; Long Li
Journal:  Front Immunol       Date:  2022-04-07       Impact factor: 8.786

Review 7.  miRNA expression in COVID-19.

Authors:  Kiarash Roustai Geraylow; Romina Hemmati; Sepideh Kadkhoda; Soudeh Ghafouri-Fard
Journal:  Gene Rep       Date:  2022-07-16

Review 8.  Gene Network Analysis of the Transcriptome Impact of SARS-CoV-2 Interacting MicroRNAs in COVID-19 Disease.

Authors:  Alexandra Ioana Moatar; Aimee Rodica Chis; Catalin Marian; Ioan-Ovidiu Sirbu
Journal:  Int J Mol Sci       Date:  2022-08-17       Impact factor: 6.208

Review 9.  Neuromodulatory effects of SARS-CoV2 infection: Possible therapeutic targets.

Authors:  Sonali Kumar; Ozasvi R Shanker; Neeraj Kumari; Manjari Tripathi; P Sarat Chandra; Aparna Banerjee Dixit; Jyotirmoy Banerjee
Journal:  Expert Opin Ther Targets       Date:  2021-07-20       Impact factor: 6.902

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.